DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease

Victòria Gudiño(Institut d'Investigacions Biomèdiques de Barcelona), Azucena Salas(Hospital Clínic de Barcelona), Maria Carme Masamunt(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Martin Hemberg(Brigham and Women's Hospital), Julián Panés(Hospital Clínic de Barcelona), Berta Caballol(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), A M Corraliza(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Alba Garrido-Trigo(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Jae‐We Cho(Brigham and Women's Hospital), Íngrid Ordás(New Leaders), E Ricart
Journal of Crohn s and Colitis
January 30, 2023
10.1093/ecco-jcc/jjac190.0105
Cited by 0

Related Papers

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Transcriptome-wide noise controls lineage choice in mammalian progenitor cells
|Nature|2008|1.2k
Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map
|Nature Neuroscience|2020|505
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
|The Lancet|2022|383
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus
|Endoscopy|2009|332